1. Home
  2. ABX vs SLS Comparison

ABX vs SLS Comparison

Compare ABX & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ABX

Abacus Global Management Inc. Class A Common Stock

N/A

Current Price

$8.35

Market Cap

805.2M

Sector

Finance

ML Signal

N/A

Logo SELLAS Life Sciences Group Inc.

SLS

SELLAS Life Sciences Group Inc.

BUY

Current Price

$4.41

Market Cap

706.7M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
ABX
SLS
Founded
2004
2012
Country
United States
United States
Employees
326
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
805.2M
706.7M
IPO Year
N/A
2007

Fundamental Metrics

Financial Performance
Metric
ABX
SLS
Price
$8.35
$4.41
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
$11.00
$10.00
AVG Volume (30 Days)
666.6K
6.6M
Earning Date
03-12-2026
03-19-2026
Dividend Yield
2.27%
N/A
EPS Growth
N/A
50.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$14.85
N/A
Revenue Next Year
$6.54
$67.40
P/E Ratio
$74.88
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.18
$0.95
52 Week High
$10.54
$6.14

Technical Indicators

Market Signals
Indicator
ABX
SLS
Relative Strength Index (RSI) 37.07 43.93
Support Level $7.18 $3.35
Resistance Level $8.78 $5.01
Average True Range (ATR) 0.48 0.49
MACD -0.19 -0.12
Stochastic Oscillator 1.59 0.32

Price Performance

Historical Comparison
ABX
SLS

About ABX Abacus Global Management Inc. Class A Common Stock

Abacus Global Management Inc is a financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. The company operates through four distinct yet complementary divisions: Abacus Life Solutions, Abacus Asset Group, Abacus Intel, and Abacus Wealth Advisors. It operates through three reportable segments, Asset management, Life solutions, and Technology services. It derives the majority revenue from Life solutions segment that generates revenues by buying, selling, and trading policies, and maintaining policies until receipt of death benefits. It also generates revenue by originating life insurance policy settlements between investors or buyers, and the sellers, who is often the original policy owner.

About SLS SELLAS Life Sciences Group Inc.

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Share on Social Networks: